Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 8/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 0.74 |
| ▸ | RAB9A | P51151 | 2/20 | 0.74 |
| ▸ | POLB | P06746 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL359675 | 1.00 | GRM4 (1.00) | GRM4HTTRAB9APOLBMEN1 | |
| SCHEMBL367814 | 1.00 | GRM4 (1.00) | GRM4HTTRAB9APOLBMEN1 | |
| SCHEMBL14698148 | 1.00 | GRM4 (1.00) | GRM4HTTRAB9APOLBMEN1 | |
| SCHEMBL20277498 | 0.91 | GRM4 (0.83) | GRM4HTTRAB9APOLBMEN1 | |
| SCHEMBL17835239 | 0.84 | GRM4 (0.73) | GRM4HTTRAB9APOLBMEN1 | |
| SCHEMBL5950689 | 0.81 | GRM4 (0.68) | GRM4HTTRAB9APOLBMEN1 | |
| SCHEMBL18037299 | 0.81 | ALDH1A1 (0.78) | GRM4HTTRAB9APOLBKMT2A | |
| SCHEMBL7857347 | 0.81 | ALDH1A1 (0.78) | GRM4HTTRAB9APOLBKMT2A | |
| SCHEMBL10521314 | 0.81 | GRM4 (0.68) | GRM4HTTRAB9APOLBMEN1 | |
| SCHEMBL10521836 | 0.81 | GRM4 (0.68) | GRM4HTTRAB9APOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160250260-A1 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE NEURONAL CELLS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-09-01 | — | — | US | disclosed |
| EP-3039126-A2 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE NEURONAL CELLS | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2016-07-06 | — | — | EP | disclosed |
| WO-2015041809-A2 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE NEURONAL CELLS | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2015-03-26 | — | — | WO | disclosed |
| US-20150057166-A1 | METHOD FOR ANALYZING THE THREE DIMENSIONAL STRUCTURE OF A GPCR | CONFOMETRX, INC. | 2015-02-26 | — | — | US | disclosed |
| US-8889377-B2 | GPCR comprising an IC2 insertion | CONFOMETRX, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20140162341-A1 | METHOD AND COMPOSITION FOR CRYSTALLIZING A GPCR | CONFOMETRX, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-8470561-B2 | GPCR comprising an IC2 insertion | ConfometRX Inc. (US) | 2013-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140162341-A1 | METHOD AND COMPOSITION FOR CRYSTALLIZING A GPCR | TMIGD3, ARRB1, GPR3 | GRM4 238/4885HTT 2031/4885RAB9A 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.